US EditionPublished • loading... • Updated
InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China
Summary by The Norfolk Daily News
10 Articles
10 Articles
The Toronto Star+9 Reposted by 9 other sources
InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China
BEIJING, March 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the
·Toronto, Canada
Read Full ArticleCoverage Details
Total News Sources10
Leaning Left5Leaning Right2Center3Last UpdatedBias Distribution50% Left
Bias Distribution
- 50% of the sources lean Left
50% Left
L 50%
C 30%
R 20%
Factuality
To view factuality data please Upgrade to Premium
